

Appl. No. : **10/789,359**
Filed : **February 26, 2004**

SUMMARY OF INTERVIEW

Attendees, Date and Type of Interview

The interview was conducted on October 30, 2008 and attended by Examiner Bouchelle and Applicants' representative, Laura Johnson.

Exhibits and/or Demonstrations

None.

Identification of Claims Discussed

Claims 15, 29, 32 and 34.

Identification of Prior Art Discussed

U.S. Patent No. 6,302,855 to Lav et al.; U.S. Patent No. 6,572,545 to Knobbe et al. (column 5, lines 35-57); and U.S. Patent No. 6,175,752 to Say et al.

Proposed Amendments, Arguments and Results

Applicants' representative proposed to amend Claim 25 to recite an integrated system, "wherein the receiver and/or medicament delivery device comprises programming that automatically detects impending clinical risk and calculates a therapy recommendation responsive to the impending clinical risk, and wherein the receiver and/or the medicament delivery device further comprises programming that requires the receiver and/or the medicament delivery device to be validated and/or confirmed by a user interaction in response to a prompt on the user interface." Examiner agreed that the proposed amendments would overcome the prior of record, including Lav and Say.

Applicants' representative proposed to amend Claim 29 to recite an integrated system comprising a continuous glucose sensor, "wherein the receiver comprises programming configured to calculate a type, amount, and/or timing of a medicament to deliver via the medicament delivery device, wherein the programming configured to calculate comprises a glucose concentration measured by the single point glucose monitor as an input value." Examiner agreed that the proposed amendment would overcome the prior art, including Knobbe.

Applicants' representative proposed to amend Claim 32 to recite an integrated system "wherein the processor further comprises programming configured to validate the medicament

Appl. No. : **10/789,359**
Filed : **February 26, 2004**

delivery instructions by prompting a user to provide a biological sample to a single point glucose monitor and by validating the medicament delivery instructions responsive to data obtained from the single point glucose monitor.” Examiner agreed that the proposed amendment would overcome the prior art, including Knobbe.

Examiner suggested that Applicants amend Claim 34 to recite an integrated system “wherein the processor comprises programming configured to estimate glucose values for a second time period responsive to glucose sensor data and the host’s metabolic response.” Examiner agreed that the suggested amendment would overcome the prior art, including Knobbe.